Overview

An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

Status:
RECRUITING

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of OriV508 injection for patients with relapsed/refractory hematological malignancies.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborator:

OriCell Therapeutics Co., Ltd.